Immunogenicity Evaluating of the Multivalent COVID-19 Inactivated Vaccine against the SARS-CoV-2 Variants

It has been reported that the novel coronavirus (COVID-19) has caused more than 286 million cases and 5.4 million deaths to date. Several strategies have been implemented globally, such as social distancing and the development of the vaccines. Several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants have appeared, such as Alpha, Beta, Gamma, Delta, and Omicron. With the rapid spread of the novel coronavirus and the rapidly changing mutants, the development of a broad-spectrum multivalent vaccine is considered to be the most effective way to defend against the constantly mutating virus. Here, we evaluated the immunogenicity of the multivalent COVID-19 inactivated vaccine. Mice were immunized by multivalent COVID-19 inactivated vaccine, and the neutralizing antibodies in serum were analyzed. The results show that HB02 + Delta + Omicron trivalent vaccine could provide broad spectrum protection against HB02, Beta, Delta, and Omicron virus. Additionally, the different multivalent COVID-19 inactivated vaccines could enhance cellular immunity. Together, our findings suggest that the multivalent COVID-19 inactivated vaccine can provide broad spectrum protection against HB02 and other virus variants in humoral and cellular immunity, providing new ideas for the development of a broad-spectrum COVID-19 vaccine.

[1]  Jian Peng,et al.  Deep learning guided optimization of human antibody against SARS-CoV-2 variants with broad neutralization , 2022, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Zhixin Ma,et al.  Design of a mutation-integrated trimeric RBD with broad protection against SARS-CoV-2 , 2022, Cell discovery.

[3]  Christina C. Chang,et al.  mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant , 2021, Cell.

[4]  L. Bekker,et al.  Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa , 2021, The New England journal of medicine.

[5]  A. Sigal,et al.  SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection , 2021, medRxiv.

[6]  S. Hoehl,et al.  Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and monoclonal antibodies , 2021, medRxiv.

[7]  R. Lu,et al.  Monoclonal Antibodies against Nucleocapsid Protein of SARS-CoV-2 Variants for Detection of COVID-19 , 2021, International journal of molecular sciences.

[8]  A. Sette,et al.  Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells , 2021, Science.

[9]  R. Brink,et al.  The unique biology of germinal center B cells. , 2021, Immunity.

[10]  K. Ranjan,et al.  COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies , 2021, Biomolecules.

[11]  Mengyao Liu,et al.  Induction of Robust and Specific Humoral and Cellular Immune Responses by Bovine Viral Diarrhea Virus Virus-Like Particles (BVDV-VLPs) Engineered with Baculovirus Expression Vector System , 2021, Vaccines.

[12]  T. de Oliveira,et al.  New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications , 2021, The New England journal of medicine.

[13]  A. Iafrate,et al.  Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity , 2021, Cell.

[14]  C. Chiozzini,et al.  Simultaneous CD8+ T-Cell Immune Response against SARS-Cov-2 S, M, and N Induced by Endogenously Engineered Extracellular Vesicles in Both Spleen and Lungs , 2021, Vaccines.

[15]  A. Iafrate,et al.  Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity , 2021, Cell.

[16]  Jianwei Wang,et al.  Identification of cross-reactive CD8+ T cell receptors with high functional avidity to a SARS-CoV-2 immunodominant epitope and its natural mutant variants , 2020, bioRxiv.

[17]  P. Dormitzer,et al.  COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses , 2020, Nature.

[18]  C. Vinuesa,et al.  COVID-19 Makes B Cells Forget, but T Cells Remember , 2020, Cell.

[19]  J. Mascola,et al.  An mRNA Vaccine against SARS-CoV-2 — Preliminary Report , 2020, The New England journal of medicine.

[20]  G. Gao,et al.  Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2 , 2020, Cell.

[21]  M. Leslie.  T cells found in coronavirus patients 'bode well' for long-term immunity. , 2020, Science.

[22]  R. Rappuoli,et al.  Vaccines and global health: In search of a sustainable model for vaccine development and delivery , 2019, Science Translational Medicine.

[23]  E. Azhar,et al.  An overview of the ongoing challenges in SARS-CoV-2 global control , 2021, German Journal of Microbiology.

[24]  R. Coffman,et al.  Lymphokine control of in vivo immunoglobulin isotype selection. , 1990, Annual review of immunology.